Oncology News | pharmaphorum

News

Keytruda shadows GSK's Jemperli in endometrial cancer

GSK had just two months to celebrate the positive phase 3 result with its checkpoint inhibitor Jemperli as a first-line therapy for endometrial cancer, before Merck &

News

Roche finally drops curtain on AKT drug ipatasertib

In amongst a clutch of discontinued phase 3 programmes in Roche's fourth-quarter results update

News

Ratio raises $20m to build on its radiopharma ambitions

Boston-based biotech Ratio Therapeutics has doubled its funding at a stroke with a $20 million Series A that will be used to usher its targeted radiotherapies into clinica

News

Tumour microenvironment key in pancreatic immunotherapy

Led by researchers at the John Hopkins Kimmel Cancer Center, the

News

Trial sets up earlier use of J&J's Carvykti in myeloma

One of Johnson & Johnson's top clinical trial readouts for 2023 just generated results, which bode very well for the future prospects of multiple myeloma CAR-T Carvykti.

News

Lilly breaks new ground for BTK class with Jaypirca approval

Eli Lilly has picked up an FDA approval for its non-covalent BTK inhibitor Jaypirca in relapsed mantle cell lymphoma (MCL) patients who relapse after treatment with current drugs in the cla

Keytruda shadows GSK's Jemperli in endometrial cancer

Roche finally drops curtain on AKT drug ipatasertib

Ratio raises $20m to build on its radiopharma ambitions

Tumour microenvironment key in pancreatic immunotherapy

Trial sets up earlier use of J&J's Carvykti in myeloma

Lilly breaks new ground for BTK class with Jaypirca approval

Ipsen' Bylvay fluffs its lines in biliary atresia trial

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks